Five Below (FIVE) Same Store Sales Surge To 22.7% Tests Bullish Growth Narratives

Five Below (FIVE) has kicked off Q1 2027 with total revenue of US$1.3 billion and basic EPS of US$2.23, setting the tone for a results season where profitability and scale are front of mind for investors. The company has seen revenue move from US$970.5 million in Q1 2026 to US$1.3 billion in Q1 2027, while quarterly basic EPS shifted from US$0.75 to US$2.23 over the same period. This gives you a clear view of how the top and bottom lines are tracking. With trailing 12 month EPS at US$7.99 and net income at US$440.5 million, the story this quarter is about how improving margins are shaping the quality of those headline numbers.

See our full analysis for Five Below.

With the latest figures on the table, the next step is to see how these results line up with the dominant narratives around growth, profitability, and risk that many investors are using to frame Five Below today.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

NasdaqGS:FIVE Revenue & Expenses Breakdown as at Jun 2026
NasdaqGS:FIVE Revenue & Expenses Breakdown as at Jun 2026
Advertisement

22.7% same store growth backs up the top line

  • Same store sales growth stepped up to 22.7% in Q1 2027 from 7.1% in Q1 2026, alongside total revenue rising from US$970.5 million to US$1.29 billion over the same periods.
  • Consensus narrative points to younger customers and value focused merchandising as key drivers, and the jump in trailing 12 month earnings of 67.4% to US$440.5 million plus net margin at 8.7% versus 6.5% a year earlier supports that. At the same time, the reliance on aggressive store expansion and tariffs in the risks section reminds you that a lot of this growth is still tied to physical locations and imported discretionary goods.
    • Analysts expecting revenue growth of about 9% per year and earnings growth of roughly 8.1% per year sit well below the most bullish long term assumptions. This shows how current strength in comps is being balanced against more measured multi year expectations.
    • The five year earnings CAGR of about 7% per year is closer to those forecasts than to the latest 67.4% jump. This suggests the recent comp and earnings strength may be treated as a strong year rather than a new long term baseline.

Margins and EPS point to efficiency gains

  • Trailing 12 month basic EPS is US$7.99 on net income of US$440.5 million, up from US$6.51 on US$358.6 million a year earlier, with net margin over the last year at 8.7% compared with 6.5% in the prior period.
  • Bulls argue that operational efficiencies, supply chain work and the higher priced Five Beyond range can support margin strength. The move in trailing net income from US$263.3 million at Q1 2026 to US$440.5 million at Q1 2027, alongside Q1 2027 net income of US$123.1 million versus US$41.1 million in Q1 2026, heavily supports that case even as tariff and labor cost risks in the narratives highlight that these gains are not guaranteed to repeat in every period.
    • Forecasts for earnings growth of around 8.1% per year with revenue growth of roughly 9% per year still assume progress, but at a pace that sits between the strong trailing year and the more moderate five year earnings CAGR of about 7% per year.
    • Same store sales growth rising from 7.1% to 22.7% year on year gives bulls evidence that merchandising and pricing are resonating, even though the risk section points to tariff exposure on roughly 60% of cost of goods and rising labor costs as possible sources of future margin pressure.
Have strong comps and margin gains really changed the long term story for this retailer, or are they one strong chapter in a longer growth path that still has clear risks attached, according to bulls who focus on store expansion and merchandising? 🐂 Five Below Bull Case

Valuation premium against 24.1x P/E creates tension

  • The stock trades on a P/E of about 24.1x versus peers at 22.9x and the US Specialty Retail industry at 19.6x, with the current share price of US$192.17 also sitting above the DCF fair value of roughly US$160.95 and below the analyst price target of US$261.14.
  • Bears highlight that earnings and revenue are forecast to grow at roughly 8.1% and 9% per year, both below the broader US market figures cited in the data. The combination of a premium P/E, a price above DCF fair value and multi year growth rates close to the five year earnings CAGR of about 7% challenges the view that the recent 67.4% earnings jump alone justifies paying more than peer and industry averages for the stock.
    • Analysts still see upside, with the consensus target of about US$261.14 implying roughly 36% above the current US$192.17 price. This contrasts with the cautious stance that a premium multiple and slower forecast growth should usually command a discount, not a higher tag.
    • The trailing 12 month revenue base of about US$5.08 billion compared with US$4.76 billion a year earlier shows scale building, but the valuation discussion in the narratives makes clear that some investors are anchoring on the DCF fair value of about US$160.95 rather than the higher target price, reinforcing the tension between growth delivery and what is already priced in.
Skeptics ask whether paying a premium P/E and a price above DCF fair value makes sense when forecast growth is only modestly ahead of long term trends, especially with store expansion and cost pressures still in the mix. 🐻 Five Below Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Five Below on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of strong comps, margin questions and a valuation premium leaves you on the fence, do not wait to interrogate the numbers yourself and weigh both sides of the story. To get a balanced snapshot of what could go right and what could go wrong, start with the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Five Below carries a premium P/E over peers while its forecast earnings and revenue growth sit close to longer term trends, which raises questions about valuation support.

If paying up for modestly ahead of trend growth makes you uneasy, compare this setup with companies trading on more grounded expectations using the 47 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:FIVE

Five Below

Operates as a specialty value retailer in the United States.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0